Patent Publication Number: US-6902731-B1

Title: Methods of treating hyperproliferative disorders using retinoblastoma fusion proteins

Description:
This is a divisional application of U.S. Ser. No. 08/801,092 filed Feb. 14, 1997 now U.S. Pat. No. 6,074,850, which is a continuation-in-part of U.S. Ser. No. 08/751,517 filed Nov. 15, 1996, now abandoned. 
    
    
     BACKGROUND OF THE INVENTION 
     Both the retinoblastoma gene (RB) and transcription factor E2F play a critical role in cell growth control (for a review, see Adams, P. &amp; Kaelin, W.  Seminars in Cancer Biology  6:99-108 (1995)). The RB locus is frequently inactivated in a variety of human tumor cells. Reintroduction of a wild-type RB gene (e.g., Bookstein et al.  Science  247:712-715 (1990)) or RB protein (pRB) (e.g., Antelman et al.  Oncogene  10:697-704(1995)) into RBneg/RBmut cells can suppress growth in culture and tumorigenicity in vivo. 
     While E2F serves to activate transcription of S-phase genes, its activity is kept in check by RB. RB arrests cells by blocking exit from G into S-phase (for example, Dowdy et al.  Cell  73:499-511 (1993)) but the precise pathway of the arrest remains unclear. 
     Although E2F forms complexes with RB, complex formation is more efficient if an E2F-related protein, DP-1, is present. E2F-1 and DP-1 form stable heterodimers which bind to DNA (for example, Qin et al.  Genes and Dev.  6-:953-964 (1992)). DP-1-E2F complexes serve to cooperatively activate transcription of E2F-dependent genes. Such transcription can be repressed by pRB in the same manner as E2F-1 or DP-1 activated transcription. 
     Transcriptional repression of genes by RB in some instances can be achieved by tethering pRB to a promoter. For example, GAL4-pRB fusions bind to GAL4 DNA binding domains and repress transcription from p53, Sp-1 or AP-1 elements (Adnane, et al.  J. Biol. Chem.  270:8837-8843 (1995); Weintraub, et al.  Nature  358:259-261 (1995)). Sellers, et al. ( Proc. Natl Acad. Sci.  92:11544-11548 (1995)) disclosed fusions of amino acid residues 1-368 of E2F with amino acids 379-792 or 379-928 of RB. 
     Chang, et al. ( Science  267.518-522 (1995)) disclosed the use of a replication-defective adenovirus-RB construct in the reduction of neointima formation in two animal models of restenosis, a hyperproliferative disorders. 
     SUMMARY OF THE INVENTION 
     The instant invention provides the surprising result that a fusion of an E2F polypeptide with an RB polypeptide is more efficient in repressing transcription of the E2F promoter than RB alone, and that such fusions can cause cell cycle arrest in a variety of cell types. Such fusions can thus address the urgent need for therapy of hyperproliferative disorders, including cancer. 
     One aspect of the invention is a polypeptide comprising a fusion of a transcription factor, the transcription factor comprising a DNA binding domain, and a retinoblastoma (RB) polypeptide, the RB polypeptide comprising a growth suppression domain. Another aspect of the invention is DNA encoding such a fusion polypeptide. The DNA can be inserted in an adenovirus vector. 
     In some embodiments of the invention, the transcription factor is E2F. The cyclin A binding domain of the E2F can be deleted or nonfunctional. The E2F can comprise amino acid residues about 95 to about 194 or about 95 to about 286 in some embodiments. 
     The retinoblastoma polypeptide can be wild-type RB, RB56, or a variant or fragment thereof. In some embodiments, the retinoblastoma polypeptide comprises amino acid residues of about 379 to about 928. Preferred amino acid substitutions of the RE polypeptide include residues 2, 608, 788, 807, and 811. 
     Another aspect of the invention is an expression vector comprising DNA encoding a polypeptide, the polypeptide comprising a fusion of a transcription factor, the transcription factor comprising a DNA binding domain, and a retinoblastoma (RB) polypeptide, the RB polypeptide comprising a growth suppression domain. In some embodiments a tissue-specific promoter is operatively linked to DNA encoding the fusion polypeptide. The tissue-specific promoter can be a smooth muscle alpha actin promoter. 
     Another aspect of the invention is a method for treatment of hyperproliferative disorders comprising administering to a patient a therapeutically effective dose of an E2F-RB fusion polypeptide. The hyperproliferative disorder can be cancer. In some embodiments the hyperproliferative disorder is restenosis. The fusion polypeptide and nucleic acid encoding the fusion polypeptide can be used to coat devices used for angioplasty. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1A  (SEQ ID NO:1) depicts the predicted amino acid sequence of E2F. 
         FIG. 1B  (SEQ ID NO:2) depicts the nucleotide sequence of transcription factor E2F. 
         FIG. 2A  (SEQ ID NO:3) depicts the nucleotide sequence of pRB as disclosed by Lee, et al. ( Nature  329:642-645 (1987). 
         FIG. 2B  (SEQ ID NO:4) depicts the predicted amino acid sequence of pRB. 
         FIG. 3  is a diagrammatic representation of pCTM. 
         FIG. 4  (SEQ ID NOS: 5-18) depicts the nucleotide sequence of plasmid pCTM. 
         FIG. 5  is a diagrammatic representation of pCTMI. 
         FIG. 6  (SEQ ID NO:19) depicts the nucleotide sequence of pCTMI. 
         FIG. 7  is a diagrammatic representation of plasmid pCTMIE. 
         FIG. 8  (SEQ ID NO:33-46) depicts the nucleotide sequence of pCTMIE. 
         FIG. 9  is a diagram depicting E2F-RB fusion constructs used in the examples. All E2F constructs commenced at amino acid 95 and lacked part of the cyclin A binding domain. E2F-437 contained the DNA binding domain (black), heterodimerization domain (white), and the transactivation domain (stippled). E2F-194 contained solely the DNA binding domain. E2F-286 contained the DNA binding domain and the DP-1 heterodimerization domain. To generate E2F-194-RB56-5s and E2F-286-RBS6-5s, the E2F constructs were fused in-frame to codon 379 of RB. C706F is an inactivating point mutation. 
         FIG. 10  is a diagram depicting transcriptional repression by E2F-RB fusion constructs. 
       FIG.  11 (A-D) depicts expression of E2F-RB fusion proteins in mammalian cell lines. Extracts were prepared from cells used in E2-CAT reporter assays or in FACS assays and analyzed with an anti-RB monoclonal antibody. In panel A, the results are shown from C33A cells transfected with (3) RB56-H209, (4) RB56 wild-type, (5) RB56-5s, (6) E2F286-5s, (7) E2F194-5s, (8) E2F194, (9) E2F286, (10) E2F437. Lane (1) is an RB56 protein standard. Lane (2) is a mock transfection. In panel B, results are shown for transfection of Saos-2 cells with (1) RB56, (2,3) E2F194-5s, and (4,5) E2F286-5s. In panel C, results are shown for transfection of 5637 cells with (2,3) RB56 wild-type, (4,5) RB56-5s; (6,7) E2F194-5s; (7,8) E2F286-5s. Lane (1) is an RB56 protein standard. In panel D, results are shown for NIH-3T3 transfected (3) RB56, (4) E2F286-5s, (5) E2F194-5s. Lane (1) is an RB56 standard; lane (2) is an RB110 standard. 
         FIG. 12  depicts histogram analyses of flow cytometry of RB-expressing NIH-3T3 cells. 
         FIG. 13 , panel A, depicts a comparison of the effects of a CMV-driven recombinant adenovirus (ACN56) with two isolates of a human smooth muscle alpha actin-driven E2F-p56 fusion construct consisting of amino acids 95 through 286 of E2F linked directly and in-frame to p56 (amino acids 379-928 of RB cDNA), vs. a control virus (ACN) in a  3 H-thymidine uptake assay in the rat smooth muscle cell line A7R5. Panel (B) depicts the effects of the same constructs in the rat smooth muscle cell line A10. 
         FIG. 14  depicts a comparison of the effects of the viruses described in  FIG. 13  in non-muscle cells. Panel (A) depicts results in the breast carcinoma cell line MDA MB468. Panel (a) depicts results in the non-small cell lung cell carcinoma line H358. 
         FIG. 15 , top panel, depicts the relative infectivity by adenovirus of different cell lines as judged by the level of β-galactosidase (β-gal) staining following infection with equal amounts of a recombinant adenovirus expressing β-gal driven by a CMV promoter. H358 is non-small lung cell carcinoma cell line; MB468 is a breast carcinoma cell line; A7R5 and A10 are smooth muscle cell lines. The lower portion of the figure depicts the relative levels of p56 protein expressed in the same cells when infected with the recombinant adenovirus ACN56, in which the p56 cDNA is driven by the non-tissue specific CMV promoter. 
         FIG. 16  depicts relative protein levels in cells infected with the smooth muscle alpha actin promoter-driven E2F-p56 fusion construct (ASN286-56). UN denoted uninfected; 50, 100, 250, and 500 refer to multiplicities of infection (MOI). 
         FIG. 17  is a bar graph depicting the ratio of intima to media area (as a measurement of the inhibition of neointima formation) from cross-sections (n=9) of rat carotid arteries which were injured and treated with recombinant adenoviruses expressing either β-gal, RB (ACNRB) or p56 (ACN56), all under the control of the CMV promoter. 
         FIG. 18  is a series of three photographs depicting restenosis in a rat angioplasty model. The panel on the left depicts data from a normal animal; the central panel depicts data from an animal injured and then treated with a β-gal expressing recombinant virus; the panel on the right depicts data from an animal injured and then treated with a recombinant adenovirus expressing p56 (ACN56). 
         FIG. 19  depicts tissue-specificity of the smooth muscle alpha actin promoter, as demonstrated by its selective ability to express the β-gal transgene in muscle cells but not non-muscle cells. The panels on the left compare β-gal expression in the breast cell carcinoma line MB468 infected with either an MOI=1 with a CMV-driven β-gal (ACNBGAL) vs an MOI=100 with the smooth muscle promoter construct (ASNBGAL). The panels on the right show β-gal expression of the rat smooth muscle cell line A7R5 infected with either an MOI=1 of ACNBGAL or an MOI=50 of ASNBGAL. Expression from ASNBGAL is seen in the muscle cell line, but is absent in the non-muscle cell line, despite the higher degree of infectivity of the cells. 
         FIG. 20  depicts the ability of recombinant adenovirus expressing RB to transduce rat carotid arteries. recombinant adenovirus-treated arteries (1×10 9  pfu) were harvested two days following balloon injury and infection. Cross sections were fixed and an RB specific antibody was used to detect the presence of RB protein in the tissue. The control virus used was ACN. RB protein staining was evident in the ACNRB treated sample, especially at higher magnifications. 
         FIG. 21  depicts a comparison of the effects of a CMV-driven p56 recombinant adenovirus (ACN56E4) vs a human smooth muscle alpha-actin promoter-driven E2F-p56 fusion construct (ASN286-56) vs control adenoviral constructs containing either the CMV or smooth muscle alpha-actin promoters without a downstream transgene (ACNE3 or ASBE3-2 isolates shown, respectively). Assays were  3 H-thymidine uptake either in a smooth muscle cell line (A7R5) or a non-muscle cell line (MDA-MB468, breast carcinoma). Results demonstrated muscle tissue specificity using the smooth muscle alpha-actin promoter and specific inhibition by both the p56 and E2F-p56 transgenes relative to their respective controls. 
     
    
    
     DESCRIPTION OF THE PREFERRED EMBODIMENT 
     The instant invention provides RB fusion constructs including fusion polypeptides and vectors encoding them, and methods for the use of such constructs in the treatment of hyperproliferative diseases. In some preferred embodiments of the invention, an RB polypeptide is fused to an E2F polypeptide. Any E2F species can be used, typically E2F-1, -2, -3, -3, or -5 (see, e.g., Wu et al.  Mol Cell. Biol.  15:2536-2546 (1995); Ivey-Hoyle et al.  Mol. Cell. Biol.  13:7802 (1993); Vairo et al.  Genes and Dev.  9:869 (1995); Beijersbergen et al.  Genes and Dev.  8:2680 (1994)); Ginsberg et al.  Genes and Dey.  8:2665 (1994); Buck et al. Oncogene 11:31 (1995)), more typically E2F-1. Typically, the EF2 polypeptide comprises at least the DNA binding domain of E2F, and may optionally include the cyclin A binding domain, the heterodimerization domain, and/or the transactivation domain. Preferably, the cyclin A binding domain is not functional. The nucleotide and amino acid sequence of E2F referred to herein are those of Genbank HWME2F, shown in  FIG. 1A and 1B . Nucleic acid, preferably DNA, encoding such an EF2 polypeptide is fused in reading frame to an RB polypeptide. The RB polypeptide can be any RB polypeptide, including conservative amino acid variants, allelic variants, amino acid substitution, deletion, or insertion mutants, or fragments thereof. Preferably, the growth suppression domain, i.e., amino acids residues 379-928, of the RB polypeptide is functional (Hiebert, et al.  MCB  13:3384-3391 (1993); Qin, et al.  Genes and Dev.  6:953-964 (1992)). In some embodiments, wild-type pRB110 is used. More preferably, a truncated version of RB, RB56, is used. RB56 comprises amino acid residues 379-928 of pRB110 (Hiebert, et al.  MCB  13:3384-3391 (1993); Qin, et al.  Genes and Dev.  6:953-964 (1992)). In some embodiments, amino acid variants of RB at positions 2, 608, 612, 788, 807, or 811, are used singly or in combination. The variant RB56-5s comprises wild-type RB56 having alanine substitutions at 608, 612, 788, 807, and 811. Numbering of RB amino acids and nucleotides is according to the RB sequence disclosed by Lee, et al. ( Nature  329:642-645 (1987)), hereby incorporated by reference in its entirety for all purposes. (FIG.  2 ). 
     Nucleic acids encoding the polypeptides of the invention can be DNA or RNA. The phrase “nucleic acid sequence encoding” refers to a nucleic acid which directs the expression of a specific protein or peptide. The nucleic acid sequences include both the DNA strand sequence that is transcribed into RNA and the RNA sequence that is translated into protein. The nucleic acid sequences include both the full length nucleic acid sequences as well as non-full length sequences derived from the full length protein. It is further understood that the sequence includes the degenerate codons of the native sequence or sequences which may be introduced to provide codon preference in a specific host cell. 
     The term “vector” as used herein refers to viral expression systems, autonomous self-replicating circular DNA (plasmids), and includes both expression and nonexpression plasmids. Where a recombinant microorganism or cell culture is described as hosting an “expression vector,” this includes both extrachromosomal circular DNA and DNA that has been incorporated into the host chromosome(s). Where a vector is being maintained by a host cell, the vector may either be stably replicated by the cells during mitosis as an autonomous structure, or is incorporated within the host&#39;s genome. A vector contains multiple genetic elements positionally and sequentially oriented, i.e., operatively linked with other necessary elements such that nucleic acid in the vector encoding the constructs of the invention can be transcribed, and when necessary, translated in transfected cells. 
     The term “gene” as used herein is intended to refer to a nucleic acid sequence which encodes a polypeptide. This definition includes various sequence polymorphisms, mutations, and/or sequence variants wherein such alterations do not affect the function of the gene product. The term “gene” is intended to include not only coding sequences but also regulatory regions such as promoters, enhancers, and termination regions. The term further includes all introns and other DNA sequences spliced from the MRNA transcript, along with variants resulting from alternative splice sites. 
     The term “plasmid” refers to an autonomous circular DNA molecule capable of replication in a cell, and includes both the expression and nonexpression types. Where a recombinant microorganism or cell culture is described as hosting an “expression plasmid”, this includes both extrachromosomal circular DNA molecules and DNA that has been incorporated into the host chromosome(s). Where a plasmid is being maintained by a host cell, the plasmid is either being stably replicated by the cells during mitosis as an autonomous structure or is incorporated within the host&#39;s genome. 
     The phrase “recombinant protein” or “recombinantly produced protein” refers to a peptide or protein produced using non-native cells that do not have an endogenous copy of DNA able to express the protein. The cells produce the protein because they have been genetically altered by the introduction of the appropriate nucleic acid sequence. The recombinant protein will not be found in association with proteins and other subcellular components normally associated with the cells producing the protein. The terms “protein” and “polypeptide” are used interchangeably herein. 
     In general, a construct of the invention is provided in an expression vector comprising the following elements linked sequentially at appropriate distances for functional expression: a tissue-specific promoter, an initiation site for transcription, a 3′ untranslated region, a 5′ mRNA leader sequence, a nucleic acid sequence encoding a polypeptide of the invention, and a polyadenylation signal. Such linkage is termed “operatively linked.” Enhancer sequences and other sequences aiding expression and/or secretion can also be included in the expression vector. Additional genes, such as those encoding drug resistance, can be included to allow selection or screening for the presence of the recombinant vector. Such additional genes can include, for example, genes encoding neomycin resistance, multi-drug resistance, thymidine kinase, beta-galactosidase, dihydrofolate reductase (DHFR), and chloramphenicol acetyl transferase. 
     In the instant invention, tissue-specific expression of the RB constructs of the invention is preferably accomplished by the use of a promoter preferentially used by a tissue of interest. Examples of tissue-specific promoters include the promoter for creatine kinase, which has been used to direct the expression of dystrophin cDNA expression in muscle and cardiac tissue (Cox, et al.  Nature  364:725-729 (1993)) and immunoglobulin heavy or light chain promoters for the expression of suicide genes in B cells (Maxwell, et al.  Cancer Res.  51:4299-4304 (1991)). An endothelial cell-specific regulatory region has also been characterized (Jahroudi, et al.  Mol. Cell. Biol.  14:999-1008 (1994)). Amphotrophic retroviral vectors have been constructed carrying a herpes simplex virus thymidine kinase gene under the control of either the albumin or alpha-fetoprotein promoters (Huber, et al.  Proc. Natl. Acad. Sci. U.S.A.  88:8039-8043 (1991)) to target cells of liver lineage and hepatoma cells, respectively. Such tissue specific promoters can be used in retroviral vectors (HATZOGLOU, et al.  J. Biol. Chem.  265:17285-17293 (1990)) and adenovirus vectors (Friedman, et al.  Mol. Cell. Biol.  6:3791-3797 (1986); Wills et al.  Cancer Gene Therapy  3:191-197 (1995)) and still retain their tissue specificity. 
     In the instant invention, a preferred promoter for tissue-specific expression of exogenous genes is the human. smooth muscle alpha-actin promoter. Reddy, et al. ( J. Cell Biology  265:1683-1687 (1990)) disclosed the isolation and nuclectide sequence of this promoter, while Nakano, et al. ( Gene  99:285-289 (1991)) disclosed transcriptional regulatory elements in the 5′ upstream and the first intron regions of the human smooth muscle (aortic type) alpha-actin gene. 
     Petropoulos, et al. ( J. Virol  66:3391-3397 (1992)) disclosed a comparison of expression of bacterial chloramphenicol transferase (CAT) operatively linked to either the chicken skeletal muscle alpha actin promoter or the cytoplasmic beta-actin promoter. These constructs were provided in a retroviral vector and used to infect chicken eggs. 
     Exemplary tissue-specific expression elements for the liver include but are not limited to HMG-COA reductase promoter (Luskey,  Mol. Cell. Biol.  7(5):1881-1893 (1987)); sterol regulatory element 1 (SRE-1; Smith et al.  J. Biol. Chem.  265(4):2306-2310 (1990); phosphoenol pyruvate carboxy kinase (PEPCK) promoter (Eisenberger et al.  Mol. Cell Biol.  12(3):1396-1403 (1992)); human C-reactive protein (CRP) promoter (Li et al.  J. Biol. Chem.  265(7):4136-4142 (1990)); human glucokinase promoter (Tanizawa et al.  Mol. Endocrinology  6(7):1070-81 (1992); cholesterol 7-alpha hydroylase (CYP-7) promoter (Lee et al.  J. Biol. Chem.  269(20):14681-9 (1994)); beta-galactosidase alpha-2,6 sialyltransferase promoter (Svensson et al.  J. Biol Chem.  265(34):20863-8 (1990); insulin-like growth factor binding protein (IGFBP-1) promoter (Babajko et al.  Biochem Biophys. Res. Comm.  196(1):480-6 (1993)); aldolase B promoter (Bingle et al.  Biochem J.  294(Pt2):473-9 (1993)); human transferrin promoter (Mendelzon et al.  Nucl. Acids Res.  18(19);5717-21 (1990); collagen type I promoter (Houglum et al.  J. Clin. Invest.  94(2):808-14 (1994)). 
     Exemplary tissue-specific expression elements for the prostate include but are not limited to the prostatic acid phosphatase (PAP) promoter (Banas et al.  Biochim. Biophys. Acta.  1217(2):188-94 (1994); prostatic secretory protein of 94 (PSP 94) promoter (Nolet et al.  Biochim. Biophys. ACTA  1089(2):247-9 (1991)); prostate specific antigen complex promoter (Casper et al.  J. Steroid Biochem. Mol. Biol.  47 (1-6):127-35 (1993)); human glandular kallikrein gene promoter (hgt-1) (Lilja et al.  World J. Urology  11(4):188-91 (1993). 
     Exemplary tissue-specific expression elements for gastric tissue include but are not limited to the human H + /K + -ATPase alpha subunit promoter (Tamura et al.  FEBS Letters  298: (2-3):137-41 (1992)). 
     Exemplary tissue-specific expression elements for the pancreas include but are not limited to pancreatitis associated protein promoter (PAP) (Dusetti et al.  J. Biol. Chem.  268(19):14470-5 (1993)); elastase 1 transcriptional enhancer (Kruse et al.  Genes and Development  7(5):774-86 (1993)); pancreas specific amylase and elastase enhancer promoter (Wu et al.  Mol. Cell. Biol.  11(9):4423-30 (1991); Keller et al.  Genes &amp; Dev.  4(8):1316-21 (1990)); pancreatic cholesterol esterase gene promoter (Fontaine et al.  Biochemistry  30(28):7008-14 (1991)). 
     Exemplary tissue-specific expression elements for the endometrium include but are not limited to the uteroglobin promoter (Helftenbein et al.  Annal, NY Acad. Sci.  622:69-79 (1991)). 
     Exemplary tissue-specific expression elements for adrenal cells include but are not limited to cholesterol side-chain cleavage (SCC) promoter (Rice et al.  J. Biol. Chem.  265:11713-20 (1990). 
     Exemplary tissue-specific expression elements for the general nervous system include but are not limited to gamma-gamma enolase (neuron-specific enolase, NSE) promoter (Forss-Petter et al.  Neuron  5(2):187-97 (1990)). 
     Exemplary tissue-specific expression elements for the brain include but are not limited to the neurofilament heavy chain (NF-H) promoter (Schwartz et al.  J. Biol. Chem.  269(18):13444-50 (1994)). 
     Exemplary tissue-specific expression elements for lymphocytes include but are not limited to the human CGL-1/granzyme B promoter (Hanson et al.  J. Biol Chem.  266 (36):24433-8 (1991)); the terminal deoxy transferase (TdT), lambda 5, VpreB, and lck (lymphocyte specific tyrosine protein kinase p56lck) promoter (Lo et al.  Mol. Cell. Biol.  11(10):5229-43 (1991)); the humans CD2 promoter and its 3′ transcriptional enhancer (Lake et al.  EMBO J.  9(10):3129-36 (1990)), and the human NK and T cell specific activation (NKG5) promoter (Houchins et al.  Immunogenetics  37(2):102-7 (1993)). 
     Exemplary tissue-specific expression elements for the colon include but are not limited to pp60c-src tyrosine kinase promoter (Talamonti et al.  J. Clin. Invest  91(1):53-60 (1993)); organ-specific neoantigens (OSNs), mw 40kDa (p40) promoter (Ilantzis et al.  Microbiol. Immunol.  37(2):119-28 (1993)); colon specific antigen-P promoter (Sharkey et al.  Cancer  73(3 supp.) 864-77 (1994)). 
     Exemplary tissue-specific expression elements for breast cells include but are not limited to the human alpha-lactalbumin promoter (Thean et al.  British J. Cancer.  61(5):773-5 (1990)). 
     Other elements aiding specificity of expression in a tissue of interest can include secretion leader sequences, enhancers, nuclear localization signals, endosmolytic peptides, etc. Preferably, these elements are derived from the tissue of interest to aid specificity. 
     Techniques for nucleic acid manipulation of the nucleic acid sequences of the invention such as subcloning nucleic acid sequences encoding polypeptides into expression vectors, labelling probes, DNA hybridization, and the like are described generally in Sambrook et al.,  Molecular Cloning—A Laboratory Manual  (2nd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., (1989), which is incorporated herein by reference. This manual is hereinafter referred to as “Sambrook et al.” 
     Once DNA encoding a sequence of interest is isolated and cloned, one can express the encoded proteins in a variety of recombinantly engineered cells. It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of DNA encoding. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes is made here. 
     In brief summary, the expression of natural or synthetic nucleic acids encoding a sequence of interest will typically be achieved by operably linking the DNA or CDNA to a promoter (which is either constitutive or inducible), followed by incorporation into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of polynucleotide sequence of interest. To obtain high level expression of a cloned gene, it is desirable to construct expression plasmids which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. The expression vectors may also comprise generic expression cassettes containing at least one independent terminator sequence, sequences permitting replication of the plasmid in both eukaryotes and prokaryotes, i.e., shuttle vectors, and selection markers for both prokaryotic and eukaryotic systems. See Sambrook et al. 
     The E2F-RB fusion constructs of the invention can be introduced into the tissue of interest in vivo or ex vivo by a variety of methods. In some embodiments of the invention, the nucleic acid, preferably DNA, is introduced to cells by such methods as microinjection, calcium phosphate precipitation, liposome fusion, or biolistics. In further embodiments, the DNA is taken up directly by the tissue of interest. In other embodiments, the constructs are packaged into a viral vector system to facilitate introduction into cells. 
     Viral vector systems useful in the practice of the instant invention include adenovirus, herpesvirus, adeno-associated virus, minute virus of mice (MVM), HIV, sindbis virus, and retroviruses such as Rous sarcoma virus, and MoMLV. Typically, the constructs of the instant invention are inserted into such vectors to allow packaging of the E2F-RB expression construct, typically with accompanying viral DNA, infection of a sensitive host cell, and expression of the E2F-RB gene. A particularly advantageous vector is the adenovirus vector disclosed in Wills, et al.  Human Gene Therapy  5:1079-1088 (1994). 
     In still other embodiments of the invention, the recombinant DNA constructs of the invention are conjugated to a cell receptor ligand for facilitated uptake (e.g., invagination of coated pits and internalization of the endosome) through a DNA linking moiety (Wu, et al.  J. Biol. Chem.  263:14621-14624 (1988); WO 92/06180). For example, the DNA constructs of the invention can be linked through a polylysine moiety to asialo-oromucocid, which is a ligand for the asialoglycoprotein receptor of hepatocytes. 
     Similarly, viral envelopes used for packaging the constructs of the invention can be modified by the addition of receptor ligands or antibodies specific for a receptor to permit receptor-mediated endocytosis into specific cells (e.g., WO 93/20221, WO 93/14188; WO 94/06923). In some embodiments of the invention, the DNA constructs of the invention are linked to viral proteins, such as adenovirus particles, to facilitate endocytosis (Curiel, et al.  Proc. Natl. Acad. Sci. U.S.A.  88:8850-8854 (1991)). In other embodiments, molecular conjugates of the instant invention can include microtubule inhibitors (WO 94/06922); synthetic peptides mimicking influenza virus hemagglutinin (Plank, et al.  J. Biol. Chem.  269:12918-12924 (1994)); and nuclear localization signals such as SV40 T antigen (WO 93/19768). 
     In some embodiments of the invention, the RB polypeptides of the invention are administered directly to a patient in need of treatment. A “therapeutically effective” dose is a dose of polypeptide sufficient to prevent or reduce severity of a hyperproliferative disorder. As used herein, the term “hyperproliferative cells” includes but is not limited to cells having the capacity for autonomous growth, i.e., existing and reproducing independently of normal regulatory mechanisms. Hyperproliferative diseases may be categorized as pathologic, i.e., deviating from normal cells, characterizing for constituting disease, or may be categorized as non-pathologic, i.e., deviation from normal but not associated with a disease state. Pathologic hyperproliferative cells are characteristic of the following disease states: restenosis, diabetic retinopathy, thyroid hyperplasia, Grave&#39;s disease, psoriasis, benign prostatic hypertrophy, Li-Fraumeni syndrome including breast cancer, sarcomas and other neoplasms, bladder cancer, colon cancer, lung cancer, various leukemias and lymphomas. Examples of non-pathological hyperproliferative cells are found, for instance, in mammary ductal epithelial cells during development of lactation and also in cells associated with wound repair. Pathological hyperproliferative cells characteristically exhibit loss of contact inhibition and a decline in their ability to selectively adhere which implies a further breakdown in intercellular communication. These changes include stimulation to divide and the ability to secrete proteolytic enzymes. 
     The constructs of the invention are useful in the therapy of various cancers and other conditions in which the administration of RB is advantageous, including but not limited to peripheral vascular diseases and diabetic retinopathy. Although any tissue can be targeted for which some tissue-specific expression element, such as a promoter, can be identified, of particular interest is the tissue-specific administration of an RB construct for hyperproliferative disorders such as restenosis, for which the smooth muscle actin promoter is preferable. 
     The compositions of the invention will be formulated for administration by manners known in the art acceptable for administration to a mammalian subject, preferably a human. In some embodiments of the invention, the compositions of the invention can be administered directly into a tissue by injection or into a blood vessel supplying the tissue of interest. In further embodiments of the invention the compositions of the invention are administered “locoregionally”, i.e., intravesically, intralesionally, and/or topically. In other embodiments of the invention, the compositions of the invention are administered systemically by injection, inhalation, suppository, transdermal delivery, etc. In further embodiments of the invention, the compositions are administered through catheters or other devices to allow access to a remote tissue of interest, such as an internal organ. The compositions of the invention can also be administered in depot type devices, implants, or encapsulated formulations to allow slow or sustained release of the compositions. 
     The invention provides compositions for administration which comprise a solution of the compositions of the invention dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc. 
     The concentration of the compositions of the invention in the pharmaceutical formulations can vary widely, i.e., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected. 
     The compositions of the invention may also be administered via liposomes. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations the composition of the invention to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to a desired target, such as antibody, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired composition of the invention of the invention can delivered systemically, or can be directed to a tissue of interest, where the liposomes then deliver the selected therapeutic/immunogenic peptide compositions. 
     Liposomes for use in the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al.  Ann. Rev. Biophys. Bionng.  9:467 (1980), U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, incorporated herein by reference. 
     A liposome suspension containing a composition of the invention may be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the composition of the invention being delivered, and the stage of the disease being treated. 
     For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more compositions of the invention of the invention, and more preferably at a concentration of 25%-75%. 
     For aerosol administration, the compositions of the invention are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of compositions of the invention are 0.01%-20% by weight, preferably 1%-10% . The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1%-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery. 
     The constructs of the invention can additionally be delivered in a depot-type system, an encapsulated form, or an implant by techniques well-known in the art. Similarly, the constructs can be delivered via a pump to a tissue of interest. 
     In some embodiments of the invention, the compositions of the invention are administered ex vivo to cells or tissues explanted from a patient, then returned to the patient. Examples of ex vivo administration of gene therapy constructs include Arteaga et al.  Cancer Research  56(5):1098-1103 (1996); Nolta et al.  Proc Natl. Acad. Sci. USA  93(6):2414-9 (1996); Koc et al.  Seminars in Oncology  23 (1):46-65 (1996); Raper et al.  Annals of Surgery  223 (2):116-26 (1996); Dalesandro et al.  J. Thorac. Cardi. Surg.  111 (2):416-22 (1996); and Makarov et al.  Proc. Natl. Acad. Sci. USA  93(1):402-6 (1996). 
     In some embodiments of the invention, the constructs of the invention are administered to a cardiac artery after balloon angioplasty to prevent or reduce the severity of restenosis. The constructs of the invention can be used to coat the device used for angioplasty (see, for example, Willard, et al.  Circulation  89:2190-2197 (1994); French, et al.  Circulation  90:2402-2413 (1994). In further embodiments, the fusion polypeptides of the invention can be used in the same manner. 
     The following examples are included for illustrative purposes and should not be considered to limit the present invention. 
     EXAMPLES 
     Example I 
     E2F-RB Fusions 
     A. Introduction 
     In this example, expression plasmids which encode different segments of E2F fused to RB56 polypeptide were constructed. RB56 is a subfragment of full length RB which contains the “pocket” domains necessary for growth suppression (Hiebert, et al.  MCB  13:3384-3391 (1993); Qin, et al.  Genes and Dev.  6:953-964 (1992)). E2F194 contains E2F amino acids 95-194. This fragment contains only the DNA binding domain of E2F. E2F286 contains the DNA binding domain and the DP-1 heterodimerization domain. Both E2F fragments lack the N-terminal cyclin A-kinase binding domain, which appears to down-regulate the DNA binding activity of E2F (Krek et al.  Cell  83:1149-1158 (1995); Krek et al.  Cell  78:161-172 (1994)). 
     B. Construction of Vectors 
     Plasmid pCTM contains a CMV promoter, a tripartite adenovirus leader flanked by T7 and SP6 promoters, and a multiple cloning site with a bovine growth hormone (BGH) polyadenylation site and a SV-40 poly adenylation site downstream. A diagrammatic representation of pCTM is provided in FIG.  3 . The DNA sequence for pCTM is provided in FIG.  4 . 
     pCTMI was constructed from pCTM by digesting pCTM with Xho I and Not I and subcloning a 180 bp intron Xhol-Not I fragment from a pCMV-β-gal vector (Clonetech ). A diagrammatic representation of pCTMI is provided in FIG.  5 . The DNA sequence is provided in FIG.  6 . 
     pCTMIE was constructed by amplifying the SV40 enhancer from SV40 viral DNA in a polymerase chain reaction. The amplified product was digested with BglII and inserted into BamHl-digested pCMTI and ligated in the presence of BamHI. The plasmid is depicted diagrammatically in FIG.  7 . The DNA sequence is provided in FIG.  8 . 
     PCTM-RB was prepared as follows. A 3.2 KB Xba I -Cla I fragment of pETRBc (Huang et al.  Nature  350:160-162 (1991)) containing the full length human RB cDNA was ligated to Xba I-Cla I digested pCTM. pCTM-RB56 was prepared by ligating the digested pCTM to a 1.7 KB Xba 1-Cla I fragment containing the coding sequence for RBS6. pCTMI-RB, pCTMIE-RB, pCTMI-RB56(amino acids 381-928) and pCTMIE-RB56(amino acids 381-928) were all constructed by the same methods. 
     C. RB-E2F Fusion Constructs 
       FIG. 9  depicts the fusion constructs used in these studies. These E2F constructs commenced at amino acid 95 and lacked part of the cyclin A binding domain. E2F437 contained the DNA binding domain (black), heterodimerization domain (white) and transactivation domain (stippled). E2Fl94 contained solely the DNA binding domain. E2F286 contained the DNA binding domain and DP-1 heterodimerization domain. RB56-5s refers to an RB variant having alanine substitutions at amino acid residues 606, 612, 788, 807 and 811. In E2Fl94-RB56-5s and E2F286-RB56-5s, the E2F fragments were fused in frame to codon 379 of RB-5s. RB56-C706F contained an inactivating point mutation (Kaye et al.  Proc. Natl. Acad. Sci. U.S.A.  87:6922-6926 (1990)). 
     pCMV-E2F194 and pCMV-E2F437 were constructed as follows. DNA encoding amino acids 95-194 of E2F (containing the DNA binding domain) or amino acids 95-437 was amplified in a polymerase chain reaction, digested with HindII, and ligated into SmaI/HindII digested pCMV-RB56 vectors. pCMVE2F286 was constructed by digesting pCMV-E2F437 with AflII, treating the ends with DNA pol I (Klenow fragment) and religating in the presence of AflII. The blunt end ligation created a stop codon at position 287. pCMV-E2F286-5s was constructed by ligating AflII (blunt)/HindIII digested pE2F437 to a Sal I (blunt)-HindIII fragment containing the RB56-5s coding sequence. pCTMIE-E2F194-5s and pCTMIE-E2F286-RB5s were constructed by ligating EcoRI-EcoRV digested pCTMIE (4.2 KB) to HindIII (blunt)-EcoRI fragments from either pCMV-E2F194-RB5s or pCMV-E2F286-RB5s. 
     D. Promoter Repression 
     To measure the effect of the E2F-RB fusion proteins, cervical carcinoma cell line C33A (ATCC # HTB-31) was transfected with equivalent amounts of E2F194-RB56 or E2F RB56 with an E2-CAT reporter plasmid (See, e.g., Weintraub et al.  Nature  358:259-261 (1992)). 
     In the C33A assay, 250,000 C33A cells were seeded into each of well of 6-well tissue culture plates and allowed to adhere overnight. 5 μg each of pCMV-RB56, pCMV-E2F RB56, or pCMV-E2F plasmid were cotransfected (calcium phosphate method, MBS transfection kit, Stratagene) with 5 μg of indicated reporter construct E2-CAT or SVCAT) and 2.5 μg β-gal plasmid (pCMV-β, Clontech) per well into duplicate wells. Cells were harvested 72 hour after transfection and extracts were prepared. 
     In the 5637 assay, 250,000 5637 cells were seeded as described above. 1 μg each of RB or E2F-RB fusion plasmid, E2-CAT or SV-CAT reporter plasmid and pCMV-β-galactosidase were cotransfected using the lipofectin reagent (BRL, Bethesda, Md.) according to the manufacturer&#39;s instructions. 
     CAT assays were performed using either 20 μL (C33A) or 50 μL (5637) of cell extract (Germany et al. Mol. Cell. Biol. 2:1044 (1982)). TLCs were analyzed on a Phosphoimager SF (Molecular Dynamics). CAT activities were normalized for transfection efficiency according to β-galactosidase activities of each extract. β-galactosidase activities of extracts were assayed as described by Rosenthal et al. ( Meth. Enzym.  152:704 (1987)). 
     The results of these studies were as follows. Transfection of the E2-CAT reporter alone or in the presence of the nonfunctional control RB56-H209 mutant yielded relatively high CAT activity. Cotransfection of wild-type RB56 or the variant RB56-5s resulted in a 10 to 12 fold repression of CAT activity, indicating that RB56or RB56-5s are both capable of efficiently repressing E2F-dependent transcription. E2F194-RB5s and E2F286-RB5s repressed transcription approximately 50 fold. Transcriptional repression required both the RB56 and the E2F components of the fusion proteins, as expression of E2F194 and E2F286 did not mediate transcriptional repression. No repression of SV40-CAT transcription occurred with E2F-RB constructs, thus demonstrating the specificity of the transcriptional repression by E2FRB for the E2 promoter. These results are depicted diagrammatically in FIG.  10 . 
     E. Cell Cycle Arrest 
     The ability of E2F-RB fusion polypeptides to cause G1 arrest in Saos-2 (RB-/-cells) (ATCC # HTB-85) and C33A cells was investigated. Previous studies have shown that RB-mediated E2 promoter repression and G1 arrest are linked in Saos-2 cells but dissociated in C33A (RBmut) cells (Xu, et al.  PNAS  92:1357-1361 (1992)). Cells were washed in PBS and were fixed in 1 mL −20° C. 70% ethanol for 30 minutes. Cells were collected by centrifugation and resuspended in 0.5 mL 2% serum containing 10 μg/ml RNase A and incubated for 30 minutes at 37° C. 0.5 mL of PBS containing propidium iodide (100 μg/ml) was added to each sample, mixed and cells were filtered through a FACS tube capstrainer. FACS analysis was performed on a FACS-Scan (Becton-Dickenson) using doublet discrimination. 5,000-10,000 CD20+ events were analyzed. Percent of cells in G 0 /G 1 , S, and G 2 /M was determined using Modfit modeling software. 
     The results of this experiment were as follows. Both full length RB110 and the truncated version RB56, but not the control mutant RB-H209, caused G 1  arrest in Saos-2 cells (Table 1). Similarly, the RB56-5s, E2F-194-RB56-5s and E2F286-RB56-5s all were capable of arresting cells in G 0 /G 1 . Transfection of the DNA binding domain, E2F194, did not block S-phase entry in Saos-2 as previously described for rodent cells (Dobrowolski, et al.  Oncogene  9:2605-2612 (1994)). In contrast, RB110, RB56, and E2F-RB fusion proteins were not capable of arresting C33A cell lines indicating that the transcriptional repression observed in these cells does not translate into G 1  arrest. 
     The ability of the E2F-RB fusion proteins to arrest 5637 cells was also investigated,(Table 2). RB56 and RB56-5s both efficiently arrested cells in G 0 /G 1  (approximately 90% of cells in G 0 -G 1 ), whereas E2F194-RB56-5s and E2F286-RB56-5s are slightly less efficient (about 80% of cells in G 0 /G 1 ) at promoting G 0 /G 1  arrest. Without being limited to any one theory, the less efficient arrest of both Saos-2 and 5637 cells by the E2F-RB fusion proteins appears due to the lower levels of steady-state protein produced in these cells ( FIG. 11 , panels b and c). 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Cell Cycle Regulation by RB and 
               
               
                 E2F-RB fusion proteins in RBneg cells 
               
            
           
           
               
               
            
               
                   
                 % Cells 
               
            
           
           
               
               
               
               
            
               
                   
                 CD20 +   
                   
                   
               
               
                   
                 G 0 /G 1   
                 G 2 /M 
                 S-phase 
               
               
                   
                   
               
            
           
           
               
               
               
               
               
            
               
                   
                 H209 
                 52.1 
                 27.1 
                 20.8 
               
               
                   
                 p56RB 
                 78.8 
                 14.2 
                 7.0 
               
               
                   
                 p110RB 
                 70.9 
                 14.3 
                 14.8 
               
               
                   
                 p56RB-5s 
                 84.8 
                 13.2 
                 2.0 
               
               
                   
                 p56RB-p5 
                 81.3 
                 11.5 
                 7.3 
               
               
                   
                 E2F-194-5s 
                 77.8 
                 14.9 
                 7.3 
               
               
                   
                 E2F-286-5s 
                 72.2 
                 15.0 
                 12.8 
               
               
                   
                 E2F-194 
                 49.9 
                 28.0 
                 22.1 
               
               
                   
                   
               
            
           
         
       
     
                     TABLE 2                  Growth Suppression of 5637 Bladder Cells by RB       and E2F-RB fusion proteins                         % Cells                                     5637/CD20 +     G 0 /G 1     S   G 2 M                                                 CD20   59.7   16.9   20.6           RB56-C706F   57.4   16.3   24.3           RB56WT   90.7   4.12   4.88           RB56-5s   89.91   3.15   6.1           E2F1 94-5s   80.1   1.31   0           E2F-286-5s   79.21   8.1   0                        
F. Activity of Fusion Proteins in Functional RB Background
 
     The activity of the E2F-RB fusion proteins in a cellular background containing functional RB was then determined. NIH-3T3 cells were transfected with RB56 or E2F-RB56 fusions and stained with anti-RB monoclonal antibody 3C8 (Wen et al.  J. Immuno. Meth.  169:231-240 (1994)). FACS analysis was performed of the RB expressing cells. The results are shown in FIG.  12 . The non-gated population (g) shows the characteristic cell cycle distribution for NIH-3T3 cells (60% GO, 28% S, 10% G2/M). In contrast, in cells transfected with RB56 (a,b) or E2F-RB fusion proteins (c-f), greater than 90% of the RB-expressing cells were arrested in G 0 /G 1 . These data demonstrate that the ability of RB and E2F-RB56 fusions to arrest cells in G 0 /G 1  is not limited to RB negative tumor cells. The relative levels of protein expressed in transfected NIH-3T3 cells was also investigated. RB110 was not expressed efficiently in these cells. 
     Thus, these data demonstrate that E2F-RB fusion proteins are more efficient transcriptional repressors than either pRB or RB56 alone, and that RB can repress transcription by remaining bound to E2F rather than directly blocking the transactivation domain of E2F. These data support the use of E2F-RB fusions as RS agonists in both RB+ cells and in RB negative or RB mutant cells. 
     Example II 
     Tissue-Specific Expression of E2F-RB Fusions 
     A. Construction of Recombinant Adenovirus 
     In this experiment, recombinant adenoviruses comprising an RB polypeptide under the control of a CMV or smooth muscle alpha actin promoter were generated. 
     The smooth muscle α-actin promoter (bases −670 through +5, Reddy et al. “Structure of the Human Smooth Muscle α-Actin Gene.” J. Biol. Chem.  265:1683-1687 (1990), Nakano, et al. “Transcriptional Regulatory Elements In The 5′ Upstream and First Intron Regions of The Human Smooth Muscle (aortic type) α-Actin-Encoding Gene.” Gene  99:285-289 (1991) was isolated by PCR from a genomic library with 5′ Xho I and Avr II and 3′ Xba I, Cla I and Hind III restriction sites added for cloning purposes. The fragment was subcloned as an Xho 1, Hind III fragment into a plasmid for sequencing to verify base composition. A fusion construct 286-56 containing the DNA and heterodimerization domain of E2F-1 (bases 95-286) linked to p56 (amino acids 379-928 of full length RB) was subcloned as an Xba I, Cla I fragment directly downstream of the smooth muscle α-actin promoter, and this expression cassette was digested out and cloned into the plasmid pAd/ITR/IX- as an Xba I to AvrII, and Cla I fragment to create the plasmid pASN286-56. This plasmid consisted of the adenovirus type 5 inverted terminal repeat (ITR), packaging signals and Ela enhancer, followed by the human smooth muscle α-actin promoter and 286-56 cassette, and then Ad 2 sequence 4021-10462 (which contains the E1b/protein IX poly A signal) in a pBR322 background. Recombinant adenovirus was produced by standard procedures. The plasmid pASN286-56 was linearized with Ngo MI and co-transfected into 293 cells with the large fragment of Cla I digested rAd34 which has deletions in both the E3 and E4 regions of adenovirus type 5. Ad34 was a serotype 5 derivative is with a 1.9 KB deletion in early region 3 resulting from deletion of the Xba I restriction fragment extending from Ad5 coordinates 28593to 30470 and a 1.4 KB deletion of early region 4 resulting from a Taq 1 fragment of E4 (coordinates 33055-35573) being replaced with a cDNA containing E4 ORF 6 and 6/7. 
     Recombinant adenovirus produced by homologous recombination was isolated and identified by restriction digest analysis and further purified by limiting dilution. Additional control recombinant adenoviruses are described elsewhere and include the control virus ACN (CMV promoter, Wills, et al. “Gene Therapy For Hepatocellular Carcinoma: Chemosensitivity Conferred By Adenovirus-Mediated Transfer of The HSV-1 Thymidine Kinase Gene.” Cancer Gene Therapy  2:191-197 (1995)), and ACN56 (RB expressed under control of a CMV promoter). 
     ACN56 was prepared as follows. A plasmid containing p56 cDNA was constructed by replacing the p53 cDNA from the plasmid ACNP53 (Wills et al. Human Gene Therapy 5:1079-1088 (1994)) with a 1.7 KB Xba I- BamHI fragment isolated from plasmid pET 9a-Rb56 (Antelman et al.  Oncocene  10:697-704 (1995)) which contains p56 cDNA. The resulting plasmid contained amino acids 381-928 of p56, the Ad5 inverted terminal repeat, viral packaging signals and E1a enhancer, followed by the human cytomegalovirus immediate early promoter (CMV) and Ad 2 tripartite leader cDNA to drive p56 expression. The p56 cDNA was followed by Ad 2 sequence 4021-10462 in a pBR322 background. This plasmid was linearized with EcoRI and cotransfected with the large fragment of bsp 106 digested DL327 (E3 deleted; Thimmappaya et al.  Cell  31:543-551 (1982)) or h5ile4 (E4 deleted; Hemstrom et al.  J. Virol.  62:3258-3264 (1988)). Recombinant viruses were further purified by limiting dilution. 
     B. Cellular Proliferation 
     In this experiment, cell lines were infected in culture with recombinant adenovirus RB constructs to ascertain the relative expression of the RB polypeptide and the effect on cell proliferation. 
     For H358 (ATCC # Crl 5807) and MDA-MB468 (ATCC # HTB 132, breast adenocarcinoma) cells, 5,000 cell/well were plated in normal growth media in a 96 well microtiter plate (Costar) and allowed to incubate overnight at 37° C., 7% CO 2 . Viruses were serially diluted in growth media and used to infect cells at the indicated doses for 48 hours. At this point,  3 H-thymidine was added (Amersham, 0.5 μCi/well) and the cells were incubated at 37° C. for another 3 hours prior to harvest. Both A7r5 (ATCC CRL1444, rat smooth muscle) and A10 (ATCC CRL 1476, rat smooth muscle) cells were seeded at 3,000 cells/well in either DME+0.5% FCS or DME+20% FCS respectively. Virus was serially diluted in the seeding media and used to infect the cells at the doses indicated in the Figures. The infection and labelling procedure were the same for A10 cells as with the H358 and MDA-MB468 cells except that 2 μCi/well of label was used. The A7r5 cells were not infected with virus until 48 hours after seeding. Forty eight hours after infection, the serum concentration was raised to 10% FCS and 2 μCi/well of  3 H-thymidine was added and incubation continued for an additional 3 hours prior to harvest. All cells were harvested by aspirating media from the wells, trypsinization of the cells, and harvesting using a 96 well GF/C filter with a Packard Top count cell harvester. Results are plotted as the mean percentage (+/−SD) of media treated control proliferation versus dose of virus in  FIGS. 13 and 14 . 
     Thus,  FIG. 13  depicts a comparison of the effects of adenovirus p56 constructs on muscle cells A10 and A7R5 cells. The CMV-driven p56 (ACN 56) virus inhibited A10 growth to approximately the same extent as the actin promoter-driven E2F-fusion constructs (ASN586-56 #25,26). In  FIG. 14 , the effects of adenovirus constructs on inhibition of a breast cancer cell line, MDA Mβ468 and a non-small cell lung carcinoma cell line, H358, are depicted. In these experiments, actin promoter-driven E2F-p56 was ineffective, while the CMV promoter-driven p56 was effective in inhibiting growth of non-smooth muscle cells. 
     To determine whether the non-smooth muscle cells were more infectable with adenovirus than the smooth muscle cell lines used, the four cells lines, H358, MB468, A7R5, and A10 were infected at an MOI of 5 with an adenovirus expressing β-galactosidase (ACβGL; Wills, et al.  Human Gene Therapy  5:1079-1088 (1994)) and degree of β-gal staining was examined. As shown in  FIG. 15  (top), the non-smooth muscle cell lines were significantly more infectable than the smooth muscle cell lines. In a further test, cells were infected at higher multiplicities of infection (50, 100, 250, 500) with ACN56 and the amount of p56 present in the infected cells detected by autoradiography. As can be seen in  FIG. 15  (bottom), the non-muscle cell lines had significantly more p56 present, since as a result of their greater infectivity, infected cells have a greater viral load and thus more copies of the p56 template driven by the non-tissue specific CMV promoter. 
     In a further experiment, the specificity of the actin smooth muscle promoter for smooth muscle tissue was ascertained. In this experiment, β-gal expression levels in cells infected with β-gal constructs driven with different promoters were measured. As can be seen in  FIG. 19 , despite the lower infectivity of the smooth muscle cells, expression was only evident in these cells using the smooth muscle alpha actin promoter. 
       FIG. 21  depicts a comparison of the effects of a CMV driven p56 recombinant adenovirus (ACN56E4) vs a human smooth muscle alpha-actin promoter driven E2F-p56 fusion construct (ASN286-56) vs control adenoviral construct containing either the CMV or smooth muscle alpha-actin promoters without a downstream transgene (ACNE3 or ASBE3-2 isolates shown, respectively). Assays were 3H-thymidine uptake either in a smooth muscle cell line (A7R5) or a non-muscle cell line (MDA-MB468, breast carcinoma). Results demonstrated muscle tissue specificity using the smooth muscle alpha-actin promoter and specific inhibition of both the p56 and E2F-p56 transgenes relative to their respective controls. 
     C. Inhibition of Restenosis 
     The model of balloon injury was based on that described by Clowes, et al. (Clowes, Lab. Invest. 49:327-333 (1983)). Male Sprague-Dawley rats weighing 400-500 g were anesthetized with an intraperitoneal injection of sodium L3 pentobarbital (45 mg/kg. Abbot Laboratories, North Chicago, Ill.). The bifurcation of the left common carotid artery was exposed through a midline incision and the left common, internal, and external carotid arteries were temporarily ligated. A 2F embolectomy catheter (Baxter Edwards Healthcare Corp., Irvine, Calif.) was introduced into the external carotid and advanced to the distal ligation of the common carotid. The balloon was inflated with saline and drawn towards the arteriotomy site 3 times to produce a distending, deendothelializing injury. the catheter was then withdrawn. Adenovirus (1×10 9  pfu of Ad-RB (ACNRb) or Ad-p56 (ACN56) in a volume of 10 μl diluted to 100 μl with 15% (wt/vol) Poloxamer 407 (BASF, Parsippany, N.J.) or Ad-β-Gal (1×10 9  pfu, diluted as above) was injected via a canula, inserted just proximal to the carotid bifurcation into a temporarily isolated segment of the artery. The adenovirus solution was incubated for 20 minutes after which the viral infusion was withdrawn and the cannula removed. The proximal external carotid artery was then ligated and blood flow was restored to the common carotid artery by release of the ligatures. The experimental protocol was approved by the Institutional Animal Care and Use Committee and complied with the “Guide for the Care and Use of Laboratory Animals.” (NIH Publication No. 86-23, revised 1985). 
     Rats were sacrificed at 14 days following treatment with an intraperitoneal injection of pentobarbital (100 mg/kg.). The initially balloon injured segment of the left common carotid artery, from the proximal edge of the omohyoid muscle to the carotid bifurcation, was perfused with saline and dissected free of the surrounding tissue. The tissue was fixed in 100% methanol until imbedded in paraffin. Several 4-μm sections were cut from each tissue specimen. One section from each specimen was stained with hematoxylin and eosin and another with Richardson&#39;s combination elastic-trichrome stain conventional light microscopic analysis. 
     Histological images of cross sections of hematoxylin and eosin or elastic-trichrome stained arterial sections were projected onto a digitizing board (Summagraphics) and the intimal, medial and luminal areas were measured by quantitative morphometric analysis using a computerized sketching program (MACMEASURE, version 1.9, National Institute of Mental Health). 
     Results were expressed as the mean ± S.E.M. Differences between groups were analyzed using an unpaired two-tailed Student&#39;s t test. Statistical significance was assumed when the probability of a null effect was &lt;0.05. 
     Results are shown in  FIGS. 17 and  18. In  FIG. 17 , the relative inhibition of neointima formation is depicted graphically, demonstrating the ability of p56 and RB to inhibit neointima formation.  FIG. 18  provides photographic evidence of the dramatic reduction of neointima in the presence of p56. 
     Adenovirus-treated carotid arteries were harvested from rats at 2 days following balloon injury and infections. Tissue was fixed in phosphate-buffered formalin until embedded in paraffin. Tissue was cut into 4 μm cross-sections and dewaxed through xylene and graded alcohols. Endogenous peroxidase was quenched with 1% hydrogen peroxide for 30 minutes. Antigen retrieval was performed in 10mM sodium citrate buffer, pH 6.0 at 95° C. for 10 minutes. A monoclonal anti-RS antibody (AB-5, Oncogene Sciences, Uniondale, N.Y.) was applied 10 μg/ml in PBS in a humid chamber at 4° C. for 24 hours. Secondary antibody was applied from the Unitect Mouse Immunohistochemistry Kit (Oncogene Sciences, Uniondale, N.Y.) according to the manufacturer&#39;s instructions. The antibody complexes were visualized using 3,3′-diaminobenzidene (DAB, Vector Laboratories, Burlingame, Calif.). Slides were thin counterstained with hematoxylin and mounted. The results are depicted in FIG.  20 . 
     All references cited herein are hereby incorporated by reference in their entirety for all purposes.